Skip to main content

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Terminated · Phase 1 · NCT06068868

Conditions: Acute Myeloid Leukemia

At a glance

Research payments reported, 2025
$449,167
U.S. investigators named
16
Sites paid
22
Planned or actual enrollment
36

About the trial

Sponsor
AbbVie
Tested
ABBV-787 (drug)
Dates
Started 2023-11-13; completion 2025-02-25
Results posted
Not yet

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in escalating doses until the maximum tolerated dose (MTD) is determined. Approximately 60 adult participants with a diagnosis of AML will be enrolled worldwide. Participants will receive intravenous (IV) …

From ClinicalTrials.gov, last updated 2025-03-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $449,167 in research payments for this study in 2025 (194 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Yale University $115,433
  • Start Midwest LLC $63,615
  • Dana Farber Mass General Brigham Cancer Care Inc $43,850
  • City of Hope National Medical Ctr $41,555
  • Weill Medical College of Cornell University $32,995
  • Ut MD Anderson Cancer Center $29,050
  • Hospital of Univ of Pennsylvania, PA $24,360
  • Sarah Cannon Research Institute LLC $19,706
  • University of Washington Medical Ctr, WA $18,414
  • University of Chicago $17,680
  • Memorial Sloan Kettering Cancer Center $17,138
  • University of California Davis Medical Center, CA $7,382
  • Medical College of Wisconsin Inc $4,551
  • Northwestern University $4,475
  • St David S South Austin Medical Center $3,650
  • $3,320
  • Yale School of Medicine $350
  • Northwestern University Health Service Evanston $342
  • Cornell University Weill Med College $300
  • State of Maryland $250
  • Ucm Emergency Department Outpatient Pharmacy $250
  • Sarah Cannon Research Institute $250
  • Medical College of Wisconsin Medical School $250

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.